Premium
Cytomegalovirus‐associated thrombocytopenia treated with thrombopoietin receptor agonist
Author(s) -
Simpson J. D.,
Matthews G. V.,
Brighton T. A.,
Joseph J. E.
Publication year - 2016
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13181
Subject(s) - medicine , eltrombopag , cytomegalovirus , thrombopoietin , context (archaeology) , romiplostim , refractory (planetary science) , thrombopoietin receptor , immunology , agonist , immune thrombocytopenia , receptor , platelet , virus , herpesviridae , viral disease , haematopoiesis , biology , paleontology , genetics , stem cell , astrobiology
Symptomatic cytomegalovirus ( CMV ) in immunocompetent individuals is an uncommon, yet recognised, phenomenon. This report discusses a case of CMV ‐associated thrombocytopenia refractory to immunomodulation and antivirals. Ultimately, a clinicopathological response was attained with eltrombopag. This is the first report of the efficacy of thrombopoietin receptor agonists in this context. This experience provides insight into possible pathogenic mechanisms of CMV ‐associated thrombocytopenia and presents a therapeutic option.